2023-04-132024-04-302024-04-30falseSC765910TR MEDIC LTD2025-01-10falseiso4217:GBPxbrli:pureSC7659102023-04-13SC7659102024-04-30SC7659102023-04-132024-04-30SC7659102023-04-12SC7659102023-04-12SC7659102023-04-122023-04-12SC765910bus:SmallEntities2023-04-132024-04-30SC765910bus:AuditExempt-NoAccountantsReport2023-04-132024-04-30SC765910bus:FullAccounts2023-04-132024-04-30SC765910bus:PrivateLimitedCompanyLtd2023-04-132024-04-30SC765910core:WithinOneYear2024-04-30SC765910core:AfterOneYear2024-04-30SC765910core:WithinOneYear2023-04-12SC765910core:AfterOneYear2023-04-12SC765910core:ShareCapital2024-04-30SC765910core:SharePremium2024-04-30SC765910core:RevaluationReserve2024-04-30SC765910core:OtherReservesSubtotal2024-04-30SC765910core:RetainedEarningsAccumulatedLosses2024-04-30SC765910core:ShareCapital2023-04-12SC765910core:SharePremium2023-04-12SC765910core:RevaluationReserve2023-04-12SC765910core:OtherReservesSubtotal2023-04-12SC765910core:RetainedEarningsAccumulatedLosses2023-04-12SC765910core:LandBuildings2024-04-30SC765910core:PlantMachinery2024-04-30SC765910core:Vehicles2024-04-30SC765910core:FurnitureFittings2024-04-30SC765910core:OfficeEquipment2024-04-30SC765910core:NetGoodwill2024-04-30SC765910core:IntangibleAssetsOtherThanGoodwill2024-04-30SC765910core:ListedExchangeTraded2024-04-30SC765910core:UnlistedNon-exchangeTraded2024-04-30SC765910core:LandBuildings2023-04-12SC765910core:PlantMachinery2023-04-12SC765910core:Vehicles2023-04-12SC765910core:FurnitureFittings2023-04-12SC765910core:OfficeEquipment2023-04-12SC765910core:NetGoodwill2023-04-12SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-12SC765910core:ListedExchangeTraded2023-04-12SC765910core:UnlistedNon-exchangeTraded2023-04-12SC765910core:LandBuildings2023-04-132024-04-30SC765910core:PlantMachinery2023-04-132024-04-30SC765910core:Vehicles2023-04-132024-04-30SC765910core:FurnitureFittings2023-04-132024-04-30SC765910core:OfficeEquipment2023-04-132024-04-30SC765910core:NetGoodwill2023-04-132024-04-30SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-132024-04-30SC765910core:ListedExchangeTraded2023-04-132024-04-30SC765910core:UnlistedNon-exchangeTraded2023-04-132024-04-30SC765910core:MoreThanFiveYears2023-04-132024-04-30SC765910core:Non-currentFinancialInstruments2024-04-30SC765910core:Non-currentFinancialInstruments2023-04-12SC765910dpl:CostSales2023-04-132024-04-30SC765910dpl:DistributionCosts2023-04-132024-04-30SC765910core:LandBuildings2023-04-132024-04-30SC765910core:PlantMachinery2023-04-132024-04-30SC765910core:Vehicles2023-04-132024-04-30SC765910core:FurnitureFittings2023-04-132024-04-30SC765910core:OfficeEquipment2023-04-132024-04-30SC765910dpl:AdministrativeExpenses2023-04-132024-04-30SC765910core:NetGoodwill2023-04-132024-04-30SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-132024-04-30SC765910dpl:GroupUndertakings2023-04-132024-04-30SC765910dpl:ParticipatingInterests2023-04-132024-04-30SC765910dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-132024-04-30SC765910core:ListedExchangeTraded2023-04-132024-04-30SC765910dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-132024-04-30SC765910core:UnlistedNon-exchangeTraded2023-04-132024-04-30SC765910dpl:CostSales2023-04-122023-04-12SC765910dpl:DistributionCosts2023-04-122023-04-12SC765910core:LandBuildings2023-04-122023-04-12SC765910core:PlantMachinery2023-04-122023-04-12SC765910core:Vehicles2023-04-122023-04-12SC765910core:FurnitureFittings2023-04-122023-04-12SC765910core:OfficeEquipment2023-04-122023-04-12SC765910dpl:AdministrativeExpenses2023-04-122023-04-12SC765910core:NetGoodwill2023-04-122023-04-12SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-122023-04-12SC765910dpl:GroupUndertakings2023-04-122023-04-12SC765910dpl:ParticipatingInterests2023-04-122023-04-12SC765910dpl:GroupUndertakingscore:ListedExchangeTraded2023-04-122023-04-12SC765910core:ListedExchangeTraded2023-04-122023-04-12SC765910dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-04-122023-04-12SC765910core:UnlistedNon-exchangeTraded2023-04-122023-04-12SC765910core:NetGoodwill2024-04-30SC765910core:IntangibleAssetsOtherThanGoodwill2024-04-30SC765910core:LandBuildings2024-04-30SC765910core:PlantMachinery2024-04-30SC765910core:Vehicles2024-04-30SC765910core:FurnitureFittings2024-04-30SC765910core:OfficeEquipment2024-04-30SC765910core:AfterOneYear2024-04-30SC765910core:WithinOneYear2024-04-30SC765910core:ListedExchangeTraded2024-04-30SC765910core:UnlistedNon-exchangeTraded2024-04-30SC765910core:ShareCapital2024-04-30SC765910core:SharePremium2024-04-30SC765910core:RevaluationReserve2024-04-30SC765910core:OtherReservesSubtotal2024-04-30SC765910core:RetainedEarningsAccumulatedLosses2024-04-30SC765910core:NetGoodwill2023-04-12SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-12SC765910core:LandBuildings2023-04-12SC765910core:PlantMachinery2023-04-12SC765910core:Vehicles2023-04-12SC765910core:FurnitureFittings2023-04-12SC765910core:OfficeEquipment2023-04-12SC765910core:AfterOneYear2023-04-12SC765910core:WithinOneYear2023-04-12SC765910core:ListedExchangeTraded2023-04-12SC765910core:UnlistedNon-exchangeTraded2023-04-12SC765910core:ShareCapital2023-04-12SC765910core:SharePremium2023-04-12SC765910core:RevaluationReserve2023-04-12SC765910core:OtherReservesSubtotal2023-04-12SC765910core:RetainedEarningsAccumulatedLosses2023-04-12SC765910core:NetGoodwill2023-04-12SC765910core:IntangibleAssetsOtherThanGoodwill2023-04-12SC765910core:LandBuildings2023-04-12SC765910core:PlantMachinery2023-04-12SC765910core:Vehicles2023-04-12SC765910core:FurnitureFittings2023-04-12SC765910core:OfficeEquipment2023-04-12SC765910core:AfterOneYear2023-04-12SC765910core:WithinOneYear2023-04-12SC765910core:ListedExchangeTraded2023-04-12SC765910core:UnlistedNon-exchangeTraded2023-04-12SC765910core:ShareCapital2023-04-12SC765910core:SharePremium2023-04-12SC765910core:RevaluationReserve2023-04-12SC765910core:OtherReservesSubtotal2023-04-12SC765910core:RetainedEarningsAccumulatedLosses2023-04-12SC765910core:AfterOneYear2023-04-132024-04-30SC765910core:WithinOneYear2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:CostValuation2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-132024-04-30SC765910core:Non-currentFinancialInstrumentscore:CostValuation2024-04-30SC765910core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-30SC765910core:Non-currentFinancialInstrumentscore:CostValuation2023-04-12SC765910core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-04-12SC765910core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-04-12SC765910bus:Director12023-04-132024-04-30SC765910bus:Director22023-04-132024-04-30

TR MEDIC LTD

Registered Number
SC765910
(Scotland)

Unaudited Financial Statements for the Period ended
30 April 2024

TR MEDIC LTD
Company Information
for the period from 13 April 2023 to 30 April 2024

Directors

AHMED, Raza Husan
SABOOR, Tariq

Registered Address

7 Crighton Place
Edinburgh
EH7 4NZ

Registered Number

SC765910 (Scotland)
TR MEDIC LTD
Balance Sheet as at
30 April 2024

Notes

2024

£

£

Fixed assets
Intangible assets3593,048
Tangible assets424,873
617,921
Current assets
Stocks560,000
Debtors6439,865
Cash at bank and on hand145,796
645,661
Creditors amounts falling due within one year7(1,246,785)
Net current assets (liabilities)(601,124)
Total assets less current liabilities16,797
Provisions for liabilities8(5,272)
Net assets11,525
Capital and reserves
Called up share capital4
Profit and loss account11,521
Shareholders' funds11,525
The financial statements were approved and authorised for issue by the Board of Directors on 10 January 2025, and are signed on its behalf by:
AHMED, Raza Husan
Director
SABOOR, Tariq
Director

Registered Company No. SC765910
TR MEDIC LTD
Notes to the Financial Statements
for the period ended 30 April 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of pharmacy services and is recognised at the point when services are rendered and goods are sold.
Operating leases
Rentals payable under operating leases are charged to the profit and loss account on a straight-line basis over the period of the lease.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account. Goodwill is amortised over its expected useful life which is estimated to be ten years.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost and subsequently at cost less depreciation. Depreciation is provided on all tangible fixed assets as follow :

Reducing balance (%)
Office Equipment20
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Stock consists of unsold medicines at the year end.
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortized cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortized. Classification of financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Basic financial liabilities Basic financial liabilities, including creditors, loans from fellow group companies are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortized. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortized cost using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

2024
Average number of employees during the year13
3.Intangible assets

Goodwill

Total

££
Cost or valuation
Additions638,160638,160
At 30 April 24638,160638,160
Amortisation and impairment
Charge for year45,11245,112
At 30 April 2445,11245,112
Net book value
At 30 April 24593,048593,048
At 12 April 23--
4.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions27,88727,887
At 30 April 2427,88727,887
Depreciation and impairment
Charge for year3,0143,014
At 30 April 243,0143,014
Net book value
At 30 April 2424,87324,873
At 12 April 23--
5.Stocks

2024

£
Finished goods60,000
Total60,000
6.Debtors: amounts due within one year

2024

£
Trade debtors / trade receivables312,458
Other debtors110,889
Prepayments and accrued income16,518
Total439,865
7.Creditors: amounts due within one year

2024

£
Trade creditors / trade payables198,101
Taxation and social security9,926
Other creditors1,038,758
Total1,246,785
8.Provisions for liabilities

2024

£
Net deferred tax liability (asset)5,272
Total5,272
9.Operating lease commitments
At 30/04/2024, the company had total commitments under non-cancellable operating rent leases over the remaining life of those leases of £37,441.
10.Related party transactions
Included in other debtor is an amount of £34,000 due from The Eye Clinic (Scotland) Ltd, a company connected to the director Tariq Saboor. Included in other creditors is an amount of £98,336 due to the director Raza Ahmed and £835,321 due to the director Tariq Saboor.
11.Controlling party
The ultimate controlling party is TR Pharma Holdings Ltd and its registered office address is 2nd Floor Grove House, 55 Lowlands Road, Harrow, Middlesex, England, HA1 3AW.
12.Change in reporting period and impact on comparability
Reporting period This is the first time the company has presented its financial statements since its incorporation. Hence, the financial statements presented are for the period of more than twelve months with no comparatives.